Antagonizing the angiotensin II subtype 1 receptor: A focus on olmesartan medoxomil

Clinical Therapeutics

Volumn 26, Issue SUPPL. A, 2004, Pages

  Nussberger, Jürg ^a   Koike, Hiroyuki ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

ACE inhibitor; Angioedema; Angiotensin II receptor antagonist; Bradykinin; Hypertension; Losartan; Olmesartan medoxomil

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; LRB 081; OLMESARTAN; RENIN INHIBITOR; SARALASIN; SARTAN; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTERY CONSTRICTION; CARDIOVASCULAR DISEASE; COUGHING; DOG; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; GUINEA PIG; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY INJURY; NONHUMAN; PRESSOR RESPONSE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 2342620112     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90141-5     Document Type: Article

References (12)

1. Weber MA. Interrupting the renin-angiotensin system: The role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens. 1999;12:189S-194S.
2. Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J. 2000;139:S2-S8.
3. Brunner HR, Nussberger J, Waeber B. Inhibitors of the renin-angiotensin system. Arzneimittelforschung. 1993;43:274-278.
4. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567-574.
5. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
6. 1 receptor antagonist. J Hypertens. 2001;19(Suppl 1):S3-S14.
7. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension. The Omipatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
8. Ramsay LE, Yeo WW. ACE inhibitors, angiotensin II receptor antagonists and cough. J Hum Hypertens. 1995;9(Suppl 5):S51-S54.
9. Lacourciere Y, Brunner H, Irwing R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens. 1994;12:1387-1393.
10. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-107.
11. Lacourciere Y. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract. 1999;53:99-103.
12. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.